Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab after alemtuzumab for autoimmune adverse event prevention in relapsing-remitting multiple sclerosis
ACTRN12621001502820Phase 3Recruiting
- Sponsor
- Griffith University
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of rituximab and alemtuzumab in multiple sclerosis (MS) (2 arms), sponsored by Griffith University. Started May 2022; status: recruiting.
02
Drugs
rituximabalemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12621001502820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001502820.